24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients.

E Randy CravenThomas WaltersWilliam C ChristieDouglas G DayRichard A LewisMargot L GoodkinMichelle ChenVeronica WangsadipuraMichael R RobinsonMarina Bejaniannull null

Published in: Drugs (2020)

Bimatoprost SR showed favorable efficacy and safety profiles up to 24 months, with all evaluated dose strengths demonstrating overall IOP-reducing effects comparable to those of topical bimatoprost. Targeted and sustained delivery of bimatoprost resulted in protracted IOP lowering, suggesting that Bimatoprost SR may represent a transformational new approach to glaucoma therapy. Clinicaltrials.gov identifier: NCT01157364.

Keyphrases

clinical trial
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
peritoneal dialysis
cancer therapy
bone marrow
open label
mesenchymal stem cells
phase iii
wound healing